BioCentury | Jul 15, 2020
Product Development

INmune therapy shows promise in Alzheimer’s, but cognitive test still to come

...produce inflammatory cytokines if given the right trigger, INmune President, CEO and acting CMO Raymond Tesi...
...which then cause synaptic pruning and affect the ability of cells to make myelin, said Tesi...
...block transmembrane TNF, which protects neurons, improves immune response, promotes remyelination and improves synaptic function, Tesi...
BioCentury | May 12, 2017
Financial News

BC Platforms completes $10M series B round

...Switzerland) raised $10 million in a series B round led by Debiopharm Innovation Fund and Tesi...
BioCentury | Mar 11, 2013
Emerging Company Profile

FPRT Bio: Neutralizing neuroinflammation

...Tesi and three other individual investors licensed exclusive rights to the protein and founded FPRT. Tesi...
...there are already multiple anti-TNF compounds on the market for RA. On the other hand, Tesi...
...raised: $200,000 Investors: Sue Preston, Richard Rainey, R.J. Tesi and an undisclosed individual CEO: R.J. Tesi...
BioCentury | Nov 8, 2010
Company News

Coronado Biosciences management update

...Pharmaceuticals Inc. , which was acquired by Endo Pharmaceuticals Holdings Inc. ; he replaces R.J. Tesi...
BioCentury | Jan 15, 2009
Cover Story

(Back)boning up on polyketides

...since found that the C5 quinone group of doxorubicin also contributes to cardiotoxicity, said Raymond Tesi...
...concluded that both structural elements must be removed from the anthracycline structure to eliminate cardiotoxicity," Tesi...
...to begin a Phase II trial in relapsed small cell lung cancer (SCLC) this year. Tesi...
BioCentury | Dec 4, 2008
Tools & Techniques

Hunting down HER2

...not surprised that they can get NK cells to attack HER2-positive cancer cells," said R.J. Tesi...
...kill cancer cells" as a result of binding the target cells via HER2. According to Tesi...
...said such trials would require "a dedicated, highly specialized center" rather than a typical clinic. Tesi...
BioCentury | Jul 14, 2008
Emerging Company Profile

Coronado: Cancer conquistador

...heart. Physicians limit the dose but would rather not use them,” according to CEO R.J. Tesi...
...the compound’s side effects. “Gem figured out two portions of the compound that cause cardiotoxicity,” Tesi...
...two portions, and has not shown cardiotoxicity or gastrointestinal toxicity in rabbit studies, he said. Tesi...
BioCentury | Jul 14, 2008
Emerging Company Profile

Corporate Profile

...focus: Cancer Clinical status: Phase I Founded: 2007 by Bert Liang, Lindsay Rosenwald and R.J. Tesi...
...Investors: Capital Strategies Advisors, Paramount BioSciences, and an undisclosed U.S. private equity fund CEO: R.J. Tesi...
BioCentury | Jun 11, 2007
Company News

Coronado Biosciences management update

...Coronado Biosciences Inc. , San Diego, Calif. Business: Cancer Hired: Raymond Tesi as president and CEO...
BioCentury | Apr 14, 2003
Product Development

Digesting SangStat's IBD data

...significant. "I don't think the compound was attacking the wrong cytokines in Crohn's," said Raymond Tesi...
...primary endpoints of response and remission were measured. "I'd like to treat for longer," said Tesi...
...optimistic." Despite similar underlying molecular mechanisms, the diseases affect different areas of the bowel, which Tesi...
Items per page:
1 - 10 of 10
BioCentury | Jul 15, 2020
Product Development

INmune therapy shows promise in Alzheimer’s, but cognitive test still to come

...produce inflammatory cytokines if given the right trigger, INmune President, CEO and acting CMO Raymond Tesi...
...which then cause synaptic pruning and affect the ability of cells to make myelin, said Tesi...
...block transmembrane TNF, which protects neurons, improves immune response, promotes remyelination and improves synaptic function, Tesi...
BioCentury | May 12, 2017
Financial News

BC Platforms completes $10M series B round

...Switzerland) raised $10 million in a series B round led by Debiopharm Innovation Fund and Tesi...
BioCentury | Mar 11, 2013
Emerging Company Profile

FPRT Bio: Neutralizing neuroinflammation

...Tesi and three other individual investors licensed exclusive rights to the protein and founded FPRT. Tesi...
...there are already multiple anti-TNF compounds on the market for RA. On the other hand, Tesi...
...raised: $200,000 Investors: Sue Preston, Richard Rainey, R.J. Tesi and an undisclosed individual CEO: R.J. Tesi...
BioCentury | Nov 8, 2010
Company News

Coronado Biosciences management update

...Pharmaceuticals Inc. , which was acquired by Endo Pharmaceuticals Holdings Inc. ; he replaces R.J. Tesi...
BioCentury | Jan 15, 2009
Cover Story

(Back)boning up on polyketides

...since found that the C5 quinone group of doxorubicin also contributes to cardiotoxicity, said Raymond Tesi...
...concluded that both structural elements must be removed from the anthracycline structure to eliminate cardiotoxicity," Tesi...
...to begin a Phase II trial in relapsed small cell lung cancer (SCLC) this year. Tesi...
BioCentury | Dec 4, 2008
Tools & Techniques

Hunting down HER2

...not surprised that they can get NK cells to attack HER2-positive cancer cells," said R.J. Tesi...
...kill cancer cells" as a result of binding the target cells via HER2. According to Tesi...
...said such trials would require "a dedicated, highly specialized center" rather than a typical clinic. Tesi...
BioCentury | Jul 14, 2008
Emerging Company Profile

Coronado: Cancer conquistador

...heart. Physicians limit the dose but would rather not use them,” according to CEO R.J. Tesi...
...the compound’s side effects. “Gem figured out two portions of the compound that cause cardiotoxicity,” Tesi...
...two portions, and has not shown cardiotoxicity or gastrointestinal toxicity in rabbit studies, he said. Tesi...
BioCentury | Jul 14, 2008
Emerging Company Profile

Corporate Profile

...focus: Cancer Clinical status: Phase I Founded: 2007 by Bert Liang, Lindsay Rosenwald and R.J. Tesi...
...Investors: Capital Strategies Advisors, Paramount BioSciences, and an undisclosed U.S. private equity fund CEO: R.J. Tesi...
BioCentury | Jun 11, 2007
Company News

Coronado Biosciences management update

...Coronado Biosciences Inc. , San Diego, Calif. Business: Cancer Hired: Raymond Tesi as president and CEO...
BioCentury | Apr 14, 2003
Product Development

Digesting SangStat's IBD data

...significant. "I don't think the compound was attacking the wrong cytokines in Crohn's," said Raymond Tesi...
...primary endpoints of response and remission were measured. "I'd like to treat for longer," said Tesi...
...optimistic." Despite similar underlying molecular mechanisms, the diseases affect different areas of the bowel, which Tesi...
Items per page:
1 - 10 of 10